RYR2 and cancer: Co-occurrence of genetic mutations in tumors with PARP1 alterations involved some genes that were enriched in transcriptional misregulation in cancer pathways (e.g., H3F3A, HIST3H3) and calcium signaling pathways (e.g., ITPKB, RYR2) (Figure 1B).